GlassScriptPhysician profile
Troy D Potter
NPI 1265432645
$3,104.07
in general payments reported to CMS, 2019-2025
33 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $142 · 2021: $379 · 2022: $424 · 2023: $705 · 2024: $659 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.27 | 2021-2025 | |
| Amgen INC. | $326.33 | 2019-2025 | Prolia, Evenity, Repatha |
| Novartis Pharmaceuticals Corporation | $282.33 | 2022-2025 | |
| Pfizer INC. | $228.82 | 2021-2025 | |
| Glaxosmithkline, LLC. | $142.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $123.38 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $121.97 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $120.70 | 2019-2020 | |
| Novo Nordisk INC | $97.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $88.54 | 2022-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $88.19 | 2019-2021 | |
| Lilly USA, LLC | $79.74 | 2021-2024 | Jardiance, Zepbound, Emgality |
| Corcept Therapeutics | $70.61 | 2025 | Korlym |
| Evoke Pharma, INC. | $53.15 | 2022-2025 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.48 | 2024 | Synjardy, Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.31 | 2021-2024 | Xifaxan |
| Eisai INC. | $47.10 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $40.31 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $30.85 | 2023-2024 | Veozah |
| Arbor Pharmaceuticals, INC. | $28.19 | 2021-2022 | |
| Genzyme Corporation | $26.98 | 2022 | |
| Optinose US, INC. | $26.96 | 2024 | |
| Horizon Therapeutics Plc | $25.89 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $25.13 | 2025 | Rexulti |
| Ardelyx, INC. | $24.50 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $23.06 | 2021 | |
| Boston Scientific Corporation | $21.03 | 2024 | Watchman Flx |
| Exact Sciences Corporation | $14.41 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $13.19 | 2020 | |
| Esperion Therapeutics, INC. | $13.11 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.95 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $11.13 | 2019 | |
| Braintree Laboratories, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.